المؤلفون: Colomban, O, Clamp, A, Cook, A, McNeish, IA, You, B

المصدر: JCO clinical cancer informatics , 7 (7) , Article e2200188. (2023)

مصطلحات موضوعية: Humans, Female, Prognosis, Ovarian Neoplasms, Carboplatin, Carcinoma, Ovarian Epithelial, Paclitaxel

وصف الملف: application/pdf

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10169187/1/cci.22.00188.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10169187Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10169187/1/cci.22.00188.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10169187Test/

المؤلفون: You, B., Purdy, C., Copeland, L.J., Swisher, E.M., Bookman, M.A., Fleming, G., Coleman, R., Randall, L.M., Tewari, K.S., Monk, B.J., Mannel, R.S., Walker, J.L., Cappuccini, F., Cohn, D., Muzaffar, M., Mutch, D., Wahner-Hendrickson, A., Martin, L., Colomban, O., Burger, R.A.

المساهمون: HonorHealth Research Institute, University of Arizona

المصدر: Journal of Clinical Oncology

العلاقة: You, B., Purdy, C., Copeland, L. J., Swisher, E. M., Bookman, M. A., Fleming, G., . & Burger, R. A. (2022). Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. Journal of clinical oncology, 40(34), 3965.; http://hdl.handle.net/10150/670409Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.22.01207Test
http://hdl.handle.net/10150/670409Test

المؤلفون: Carrot, A., Oudard, S., Colomban, O., Fizazi, K., Sartor, O., Freyer, G., You, B.

المصدر: Annals of Oncology ; volume 33, page S1195 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.1908Test
https://api.elsevier.com/content/article/PII:S0923753422037590?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422037590?httpAccept=text/plainTest

المؤلفون: Becker, O., Chevrier, M., Gladieff, L., Joly Lobbedez, F., Ray-Coquard, I.L., Floquet, A., Pomel, C., Costaz, H., Pautier, P., De La Motte Rouge, T., Sabatier, R., Classe, J-M., Leblanc, E., Marchal, F., Colombo, P-E., Barranger, E., Colomban, O., Bosquet, L., You, B., Rodrigues, M.J.

المصدر: Annals of Oncology ; volume 33, page S819 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.724Test
https://api.elsevier.com/content/article/PII:S0923753422025753?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422025753?httpAccept=text/plainTest

المؤلفون: Pierre-Alexandre, J, Moret, S, Colomban, O, Combe, P, Abadie-Lacourtoisie, S, Meunier, J, Floquet, A, Venat-Bouvet, L, Louvet, C, Favier, L, Follana, P, Lotz, JP, Del Piano, F, Leheurteur, M, Alliot, CR, De Rauglaudre, G, Raban, N, Chevalier-Place, A, Leary, A, You, B

المصدر: Translational research biomarkers

الإتاحة: https://doi.org/10.1136/ijgc-2021-esgo.601Test

المؤلفون: Colomban, O, Tod, M, Peron, J, Perren, TJ, Leary, A, Cook, AD, Sajous, C, Freyer, G, You, B

المصدر: JNCI Cancer Spectrum , 4 (3) , Article pkaa026. (2021)

مصطلحات موضوعية: chemotherapy regimen, ca-125 antigen, phase 3 clinical trials, kinetics, neoplasms, ovarian cancer, bevacizumab, elimination rate constant, progression-free survival, datasets

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10123745/1/pkaa026.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10123745Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10123745/1/pkaa026.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10123745Test/

المؤلفون: Corbaux, P., You, B., Glasspool, R.M., Yanaihara, N., Tinker, A.V., Lindemann, K., Ray-Coquard, I.L., Mirza, M.R., Subtil, F., Colomban, O., Peron, J., Karamouza, E., McNeish, I., Hinsley, S., Kagimura, T., Welch, S., Lewsley, L-A., Paoletti, X., Cook, A.

المصدر: Annals of Oncology ; volume 32, page S744 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1193Test
https://api.elsevier.com/content/article/PII:S0923753421034220?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421034220?httpAccept=text/plainTest

المؤلفون: Carrot, A., Elaidi, R-T., Colomban, O., Maillet, D., Tod, M., You, B., Oudard, S.

المصدر: Annals of Oncology ; volume 32, page S666 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1147Test
https://api.elsevier.com/content/article/PII:S0923753421033767?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421033767?httpAccept=text/plainTest

المؤلفون: Colomban, O, Tod, M, Peron, J, Perren, TJ, Leary, A, Cook, AD, Sajous, C, Freyer, G, You, B

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/167360/1/Bevacizumab%20for%20Newly%20Diagnosed%20Ovarian%20Cancers%20Best%20Candidates%20Among%20High-Risk%20Disease%20Patients%20%28ICON-7%29.pdfTest; Colomban, O, Tod, M, Peron, J et al. (6 more authors) (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4 (3). pkaa026. pkaa026-. ISSN 1475-4029

الإتاحة: https://eprints.whiterose.ac.uk/167360Test/
https://eprints.whiterose.ac.uk/167360/1/Bevacizumab%20for%20Newly%20Diagnosed%20Ovarian%20Cancers%20Best%20Candidates%20Among%20High-Risk%20Disease%20Patients%20%28ICON-7%29.pdfTest

المؤلفون: Van Wagensveld, L., Colomban, O., Van Der AA, M., Tod, M., Sonke, G.S., Kruitwagen, R., You, B.

المصدر: Annals of Oncology ; volume 31, page S633 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.986Test
https://api.elsevier.com/content/article/PII:S0923753420409822?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420409822?httpAccept=text/plainTest